Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
248.79
+14.52 (6.20%)
Nov 20, 2024, 4:00 PM EST - Market closed
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,100 employees as of December 31, 2023. The number of employees increased by 98 or 4.90% compared to the previous year.
Employees
2,100
Change (1Y)
98
Growth (1Y)
4.90%
Revenue / Employee
$997,521
Profits / Employee
-$158,221
Market Cap
32.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
IQVIA Holdings | 87,000 |
Humana | 67,600 |
Centene | 67,000 |
Cardinal Health | 48,900 |
Mettler-Toledo International | 17,300 |
IDEXX Laboratories | 11,000 |
DexCom | 9,600 |
Veeva Systems | 7,172 |
ALNY News
- 3 days ago - Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose - Business Wire
- 16 days ago - Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
- 20 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity - Business Wire
- 21 days ago - Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 - Business Wire
- 24 days ago - Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch - Seeking Alpha
- 4 weeks ago - Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire